177Lu-PSMA-617 (177Lu-Vipivotide tetratexan) is a 177Lu labeled peptide developed for the therapy of metastasized castrate resistant prostate cancer (mCRPC). This molecule is an IP protected molecule back-up of PSMA-11.
PSMA-617 is primarily developed as a therapeutic agent labeled with 177Lu.
Data published in December 2016 based on 145 patients with mCRPC who received treatment with 177Lu-PSMA-617 for radioligand therapy and treated in 12 therapy centers show that 45% of patients had a positive response to treatment after receiving all treatment cycles, and 40% responded after one cycle.
Obtained US FDA marketing authorization in March 2022 (under the name of PluvictoTM ).
Leading Emitter: beta electrons (β–)